Asialoglycoprotein receptor (ASGPR)-targeted lipid nanoparticles are lipid-based delivery systems functionalized with carbohydrate ligands that recognize ASGPR on hepatocytes. ASGPR is a calcium-dependent lectin that preferentially recognizes terminal, non-reducing N-acetylgalactosamine (GalNAc) and galactose (Gal) residues. Following ligand recognition, the receptor can mediate nanoparticle internalization through receptor-associated endocytosis, providing a route for directing encapsulated payloads toward liver parenchymal cells.
Three major ligand architectures can be considered: multivalent GalNAc-lipid-integrated LNPs, galactose-lipid-conjugated LNPs, and galactose-rich polysaccharide-modified lipid nanocarriers. These systems differ in carbohydrate recognition, ligand valency, surface presentation, and lipid anchoring. Their suitability depends on receptor accessibility, payload properties, particle composition, and the intended delivery route. BOC Sciences provides targeted LNP development and liver-targeted LNP development services, covering ligand selection, conjugation, formulation optimization, and biological evaluation for different research applications.
Multivalent GalNAc-lipid-integrated LNPs display multiple N-acetylgalactosamine residues on their external surface through a lipid-associated targeting conjugate. GalNAc is an attractive ASGPR ligand because its recognition is generally stronger than that of monovalent galactose. When several GalNAc units are presented in a spatially organized structure, multivalent interactions can further enhance receptor binding through the cluster effect. This makes ligand valency and spatial arrangement important considerations in the design of hepatocyte-targeted nanoparticles. A typical multivalent GalNAc-lipid conjugate contains three structural regions: a GalNAc cluster, a hydrophilic spacer, and a hydrophobic lipid anchor. The GalNAc cluster provides receptor recognition, while the spacer separates the carbohydrate residues from the nanoparticle surface. The lipid anchor retains the targeting conjugate within the LNP lipid layer. The internal nanoparticle structure can contain an ionizable lipid, helper phospholipid, cholesterol, and PEG-lipid, with the composition adjusted according to the encapsulated payload.
Triantennary GalNAc structures are particularly relevant because three carbohydrate residues can provide multivalent receptor engagement. Common scaffold designs include tris(hydroxymethyl)aminomethane (Tris)-based and lysine-based structures. The carbohydrate units are connected to the central scaffold through suitable chemical linkages, while an additional functional group allows attachment to a PEG-containing lipid anchor. The orientation of each GalNAc residue should preserve the hydroxyl groups required for ASGPR recognition. A representative example is GalNAc-Lipid GL6, reported by Kasiewicz and colleagues in a 2023 study of GalNAc-LNPs for hepatic delivery of a CRISPR base-editing system. GL6 incorporated a lysine-based trivalent GalNAc scaffold, an approximately 36-unit PEG spacer, and a 1,2-di-O-octadecyl-sn-glyceryl (DSG) lipid anchor. The study compared different ligand scaffolds, spacer lengths, and lipid anchors, demonstrating that these structural variables can substantially influence ASGPR-mediated delivery.
Several parameters determine whether this architecture is suitable for a particular LNP program:
This architecture is particularly useful when an LNP requires a defined hepatocyte-recognition mechanism beyond its intrinsic liver distribution. It can be considered for siRNA, mRNA, guide RNA, and other nucleic acid delivery systems when ASGPR expression is sufficiently accessible in the intended target population. It is also relevant when an existing LNP formulation needs an additional targeting function without replacing its original payload-encapsulation mechanism.
Preparation generally involves two connected processes: synthesis of the multivalent GalNAc-lipid conjugate and incorporation of that conjugate into the LNP structure. Developing and characterizing the conjugate separately makes it easier to control ligand purity, substitution degree, and lipid-anchor integrity before nanoparticle assembly.
Step 1: Preparation of the multivalent GalNAc scaffold. GalNAc residues are chemically attached to a multifunctional scaffold, such as a Tris- or lysine-based core. Amide, ether, or other suitable linkages can be selected according to the reactive groups available on the carbohydrate and scaffold. Reaction conditions should preserve the sugar configuration and receptor-recognition groups while limiting incomplete substitution and unwanted crosslinking.
Step 2: Spacer and lipid-anchor conjugation. The multivalent carbohydrate scaffold is connected to a hydrophilic spacer, commonly based on PEG, followed by attachment to a lipid anchor. DSG, cholesterol-derived structures, and long-chain alkyl anchors represent possible structural approaches. The selected anchor should provide adequate membrane retention without interfering with the surface presentation of GalNAc. PEG molecular weight and the number of repeating units should be screened according to ligand accessibility and particle compatibility.
Step 3: Conjugate purification and chemical verification. Unreacted GalNAc, unconjugated scaffold, excess spacer, and coupling reagents should be removed. Dialysis, ultrafiltration, and chromatographic separation can be selected according to molecular weight and solubility. Nuclear magnetic resonance (NMR), mass spectrometry, and suitable chromatographic methods can help confirm molecular structure, conjugation, and product purity.
Step 4: LNP preparation and ligand incorporation. The GalNAc-lipid conjugate can be introduced during initial LNP formation or incorporated into preformed particles through post-insertion. During pre-incorporation, the conjugate is mixed with the other lipid components before nanoparticle assembly. Microfluidic mixing or another suitable formulation process can then be used to generate the payload-containing particles. The lipid nanoparticle synthesis process should be optimized to maintain particle integrity and payload encapsulation while incorporating the targeting lipid.
Step 5: Process optimization. The GalNAc-lipid molar fraction, total lipid concentration, mixing conditions, aqueous-to-organic phase ratio, and buffer composition should be evaluated systematically.
For reproducible particle preparation, microfluidic LNP production can be considered to control mixing and particle assembly. BOC Sciences can also support custom synthesis of GalNAc-containing lipid building blocks when a specific scaffold, spacer, or lipid-anchor structure is required.
Purification should remove free GalNAc-lipid conjugates, unencapsulated payload, residual solvents, and small-molecule reaction components while preserving the nanoparticle structure. The main challenge is distinguishing particle-associated conjugate from free or self-assembled lipid conjugates that may remain in the same formulation. Therefore, purification efficiency should be evaluated through direct analysis of both the nanoparticle fraction and the removed soluble fractions.
Size-exclusion chromatography: Separates nanoparticles from smaller soluble components according to hydrodynamic size. It can be useful for removing free payload and unincorporated conjugate when sufficient size differences exist. Particle recovery and possible overlap between free lipid assemblies and LNPs should be considered.
Ultrafiltration and tangential flow filtration: These approaches can concentrate particles and remove buffer-soluble components. Membrane selection should account for particle retention, free conjugate characteristics, and recovery of the encapsulated payload. Excessive concentration or membrane fouling may increase particle aggregation or reduce yield.
Dialysis and buffer exchange: Can remove residual organic solvents and low-molecular-weight components. However, dialysis alone may not adequately separate high-molecular-weight free conjugates or lipid aggregates from the LNP population.
Following purification, several complementary measurements are required:
Stability evaluation should also determine whether the GalNAc-lipid conjugate remains associated with the nanoparticle after storage, dilution, and exposure to relevant biological media. A stable particle-size distribution does not necessarily demonstrate stable ligand retention. Therefore, surface ligand content and receptor-binding activity should be reassessed after relevant stability challenges. Lipid nanoparticle stability evaluation can help investigate these changes.
Intravenous administration is a principal route for evaluating systemic delivery of GalNAc-functionalized LNPs to hepatocytes. After entering the circulation, the particles encounter plasma proteins, vascular interfaces, and hepatic tissue compartments before reaching the target cell population. The exposed GalNAc residues can interact with ASGPR on hepatocytes, supporting receptor-associated uptake. However, successful targeting depends on ligand accessibility and particle behavior throughout this process.
Several formulation characteristics should be considered when selecting the delivery strategy:
For mRNA-containing systems, the formulation should preserve both RNA encapsulation and intracellular protein expression. For siRNA, the objective is productive cytosolic delivery followed by measurable target-gene silencing. The lipid nanoparticle-mediated mRNA delivery platform provides a relevant formulation context, while the ligand layer can be optimized to improve hepatocyte recognition. Although systemic administration is the primary strategy for accessing hepatocytes through circulation, localized administration may be considered for research applications involving accessible hepatic compartments or specific local delivery objectives. Such routes should not be assumed to provide the same receptor exposure or biodistribution as intravenous administration. The final route should be selected according to the intended target cells, payload, and formulation properties.
In vivo verification should establish whether GalNAc modification improves hepatocyte-specific uptake and functional payload delivery. A useful evaluation framework separates four related outcomes: systemic distribution, liver accumulation, target-cell internalization, and intracellular payload activity. These outcomes should be measured independently because an increase in one parameter does not automatically demonstrate improvement in the others.
Whole-body and organ distribution: A traceable lipid component can be incorporated into the formulation to monitor nanoparticle-associated signals after administration. Serial imaging provides information about distribution over time, while tissue collection and quantitative analysis can compare the liver with other organs. A fluorescent signal should be interpreted cautiously because lipid-associated labels may redistribute independently of the encapsulated payload.
Hepatocyte-specific uptake: Liver tissue can be processed to obtain different cellular populations, followed by flow cytometry to quantify particle-associated signals. Confocal microscopy and tissue imaging can provide spatial information about cellular localization. The analysis should distinguish hepatocytes from hepatic macrophages and other non-parenchymal cells to determine whether the targeting ligand changes cell-specific distribution.
ASGPR-dependent recognition: Free GalNAc competition, receptor-blocking experiments, and appropriate receptor-expression comparisons can help establish whether the observed uptake depends on ASGPR. Comparisons with unmodified LNPs and formulations containing different GalNAc densities are also useful. A reduction in uptake following receptor competition provides stronger evidence of receptor involvement than liver accumulation alone.
Functional payload delivery: For mRNA formulations, reporter expression or the intended protein product can be quantified in liver tissue or isolated target cells. For siRNA, target transcript and protein levels can be measured. For CRISPR-associated payloads, target-site editing can provide a functional readout. These measurements should be compared with particle-distribution and cellular-uptake data to determine whether internalization leads to productive intracellular delivery.
BOC Sciences can support nanoparticle cellular uptake testing, nanoparticle in vivo imaging, and nanoparticle in vivo distribution analysis to help integrate tissue distribution, cell-specific uptake, and functional delivery measurements.
Table 1. Development and Evaluation Workflow for Multivalent GalNAc-Lipid-Integrated LNPs.
| Development Stage | Representative Methods and Readouts |
| GalNAc-Lipid Synthesis and LNP Preparation | Trivalent GalNAc scaffold synthesis; PEG spacer and lipid-anchor conjugation; pre-incorporation or post-insertion; microfluidic mixing. Evaluate conjugate identity, purity, ligand density, particle size, and payload encapsulation. |
| In Vitro Validation | DLS, PDI, zeta potential, cryo-TEM, GalNAc quantification, ASGPR binding, carbohydrate competition, cellular uptake, and payload activity. Assess surface accessibility, receptor recognition, and functional delivery. |
| Delivery Route | Primarily intravenous administration for systemic hepatocyte targeting; localized administration may be evaluated for specific research objectives. Assess circulation stability, hepatic exposure, and target-cell accessibility. |
| In Vivo Verification | Whole-body imaging, organ distribution, tissue flow cytometry, microscopy, receptor competition, and payload-specific expression, silencing, or editing analysis. Assess hepatocyte uptake and functional delivery separately. |
BOC Sciences provides GalNAc building blocks, custom multivalent ligand synthesis, PEG-lipid conjugation, LNP formulation, surface-density optimization, and physicochemical and biological characterization to support hepatocyte-targeted LNP development.
Galactose-lipid-conjugated LNPs use galactose residues as surface-recognition ligands for ASGPR. Galactose is a naturally recognized carbohydrate ligand of the receptor, although its binding affinity is generally lower than that of GalNAc under comparable competition conditions. Therefore, the design of Gal-functionalized LNPs often requires careful attention to ligand density, carbohydrate accessibility, and multivalent presentation.
A typical structure consists of a galactose headgroup connected to a hydrophilic spacer and a lipid anchor. Gal-PEG-lipid conjugates are particularly useful because the lipid portion can associate with the nanoparticle membrane while PEG extends the carbohydrate beyond the surrounding lipid layer. DSPE-PEG-Gal is one example of this architecture. The PEG spacer can help reduce steric interference from neighboring lipid components, although excessive PEG coverage may also change cellular interactions. A representative formulation is MCC950@Gal-LNPs, reported by Niu and colleagues in a 2026 study published in the Journal of Materials Chemistry B. The researchers used DSPE-PEG2000-Gal to introduce galactose onto the particle surface. The formulation contained DODAP, DOPE, cholesterol, and the galactose-bearing PEG-lipid, with MCC950 as the encapsulated small-molecule payload. The study investigated ASGPR-associated hepatic uptake and demonstrated the potential of galactose-functionalized LNPs for liver-directed delivery.
The structure of Gal-lipid conjugates can be adjusted according to the intended surface architecture:
Galactose-functionalized LNPs may be considered when a relatively straightforward carbohydrate-lipid conjugate is preferred or when the formulation requires a different surface architecture from multivalent GalNAc systems. They are also relevant for screening ASGPR-mediated uptake of small-molecule and nucleic acid payloads. However, the use of galactose alone does not guarantee strong receptor selectivity. Its performance should be established using receptor-dependent cellular experiments rather than inferred from the presence of the carbohydrate.
Preparation generally involves synthesis or selection of a galactose-bearing lipid conjugate, followed by its incorporation into the nanoparticle structure. The main chemical consideration is maintaining an accessible galactose recognition group while connecting the carbohydrate to a hydrophobic anchor that remains associated with the particle.
Step 1: Galactose activation and spacer attachment. A galactose derivative with a suitable reactive group can be coupled to a hydrophilic spacer. The anomeric position or another appropriate functional position can be considered for conjugation, depending on the intended molecular architecture. Reaction conditions should preserve the hydroxyl-group arrangement required for receptor recognition.
Step 2: Lipid-anchor conjugation. The spacer is connected to a suitable lipid component, such as a phospholipid-based anchor. Amide, ether, or other stable linkages can be considered according to the available functional groups. The resulting Gal-PEG-lipid should be characterized before formulation to confirm chemical identity, purity, and the presence of the intended carbohydrate structure.
Step 3: Preparation of the base LNP. The lipid composition should be selected according to the payload. For nucleic acid formulations, ionizable lipids, helper phospholipids, cholesterol, and PEG-lipids are commonly evaluated. For hydrophobic small molecules, the lipid composition may require a different balance of membrane-forming and payload-associated components. The lipid nanoparticle formulation process should establish a stable base particle before the surface modification strategy is finalized.
Step 4: Gal-lipid incorporation. Gal-PEG-lipid can be mixed with the other lipid components before particle formation or inserted into preformed LNPs. Pre-incorporation provides an opportunity to control the ligand fraction during particle assembly. Post-insertion can be considered when the original particle formulation is already optimized, but the amount of incorporated Gal-lipid and its surface distribution should be measured.
Step 5: Process adjustment. Mixing intensity, solvent removal, buffer composition, and ligand-to-total-lipid ratio should be optimized according to the particle-formation method. Nanoparticle surface functionalization services and nanoparticle conjugation services can support the development of suitable surface-linkage strategies.
Purification should remove unbound Gal-PEG-lipid, residual solvents, unencapsulated payload, and low-molecular-weight reaction components. The selected separation process should preserve the association between the lipid anchor and the nanoparticle membrane. This is particularly important when the galactose-bearing lipid is introduced by post-insertion because loosely associated conjugates may be removed or redistributed during subsequent processing.
Size-exclusion chromatography: Can separate LNPs from smaller free components based on hydrodynamic size. It is useful when the particle and free-conjugate populations exhibit sufficient separation. Fraction analysis is necessary to confirm that the collected nanoparticle fraction contains the intended Gal-lipid.
Ultrafiltration and tangential flow filtration: Can remove soluble impurities and exchange formulation buffers. Membrane cutoff and operating conditions should be selected according to particle size, free-conjugate characteristics, and desired recovery.
Dialysis: Can remove residual solvents and small-molecule components, but may be less effective for separating larger free lipid conjugates. It should therefore be combined with an appropriate analytical method to verify residual surface modifier content.
After purification, characterization should determine whether the galactose-bearing lipid has been incorporated without compromising the original particle:
For nucleic acid formulations, additional measurements should examine RNA integrity and the ability of the modified particles to retain and release their payload. For small-molecule formulations, drug loading and release behavior should be evaluated together with particle stability. Nanoparticle in vitro evaluation can integrate physicochemical and biological readouts during formulation screening. A useful stability assessment compares the modified and unmodified formulations under the same storage and biological-media conditions. Particle size, PDI, zeta potential, free Gal-lipid content, and payload retention should be considered together. A formulation that retains its particle size but loses surface galactose may no longer provide the intended receptor-recognition function.
Systemic intravenous administration is a suitable starting route for evaluating the hepatic targeting potential of Gal-functionalized LNPs. Following circulation, exposed galactose residues can interact with ASGPR on hepatocytes and promote receptor-associated internalization. However, the effectiveness of this process depends on receptor expression, ligand accessibility, and the stability of the conjugated lipid under biological conditions.
Ligand-density optimization: Because Gal generally has lower monovalent affinity than GalNAc, the number and distribution of galactose residues on the nanoparticle surface can be important. Increasing ligand density may improve receptor contact, but excessive modification can create steric crowding, increase hydrodynamic diameter, or affect colloidal stability. A controlled ligand-density screen is preferable to simply maximizing the Gal-lipid fraction.
PEG-lipid balance: PEG can help reduce nonspecific interactions and maintain particle dispersion. However, a dense PEG layer may reduce access to galactose residues. The PEG-lipid fraction and the length of the Gal-containing spacer should therefore be optimized together.
Core formulation compatibility: The ionizable or cationic lipid component should provide the required interaction with the payload and support intracellular release. Helper phospholipids and cholesterol influence membrane organization and particle stability. The galactose-bearing lipid should be incorporated at a level that does not unnecessarily disturb these core functions.
Payload-dependent delivery: Small-molecule payloads require suitable loading and release characteristics, whereas siRNA and mRNA require protection against degradation and productive cytosolic delivery. For nucleic acid applications, endosomal escape remains an independent formulation challenge even when ASGPR-mediated internalization is enhanced.
Verification should establish whether Gal-lipid modification improves ASGPR-associated uptake and functional payload delivery relative to an unmodified formulation. Because galactose can interact with other biological components and receptor abundance may vary among tissues, liver enrichment alone is insufficient to demonstrate the intended targeting mechanism.
Whole-body imaging: A traceable lipid component can be used to monitor particle-associated signals following administration. Imaging at multiple time points can provide information about distribution and clearance. The same labeling strategy should be used for modified and unmodified LNPs to support meaningful comparisons.
Organ-level biodistribution: Liver, spleen, lungs, kidneys, and other relevant tissues can be collected for quantitative analysis. Tissue-associated signals should be interpreted with respect to the administered dose, sampling time, and possible differences in clearance. A higher liver signal does not independently establish hepatocyte-specific uptake.
ASGPR-dependent uptake: Free-galactose competition, receptor-blocking experiments, and receptor-expression comparisons can help determine the contribution of ASGPR. Unmodified LNPs should be included as controls. When possible, the particle-associated signal should be quantified in separated hepatocyte and non-parenchymal cell populations.
Cellular localization: Flow cytometry can quantify particle-associated signals across different hepatic cell populations, while microscopy can show their spatial distribution. Intracellular localization analysis can help determine whether particles remain associated with the cell surface or enter intracellular compartments.
Functional payload delivery: For small-molecule payloads, tissue concentration and target-related biological readouts can be evaluated. For mRNA, protein expression can be measured, while siRNA formulations can be assessed through target transcript and protein reduction. The functional readout should be linked to the target-cell population whenever possible.
BOC Sciences can support integrated cellular and in vivo evaluation, including tissue distribution, target-cell association, intracellular localization, and functional payload assessment. These measurements provide a more complete basis for determining whether galactose functionalization improves the intended delivery pathway.
Table 2. Development and Evaluation Workflow for Galactose-Lipid-Conjugated LNPs.
| Development Stage | Representative Methods and Readouts |
| Gal-Lipid Synthesis and LNP Preparation | Galactose-spacer conjugation; lipid-anchor coupling; pre-incorporation or post-insertion; nanoprecipitation or microfluidic mixing. Evaluate conjugate purity, ligand density, particle size, and payload loading. |
| In Vitro Validation | DLS, PDI, zeta potential, morphology, Gal-lipid quantification, ASGPR binding, free-galactose competition, cellular uptake, and payload activity. Assess ligand accessibility and receptor-associated internalization. |
| Delivery Route | Primarily intravenous administration for systemic hepatocyte targeting; localized delivery may be considered for specific research applications. Evaluate particle stability, ligand retention, and target tissue exposure. |
| In Vivo Verification | Whole-body imaging, organ distribution, cell-specific uptake, microscopy, receptor competition, and payload-specific expression or activity. Distinguish liver accumulation from ASGPR-dependent hepatocyte delivery. |
BOC Sciences supports galactose-lipid building-block selection, Gal-PEG-lipid conjugation, LNP surface modification, formulation optimization, and receptor-associated delivery evaluation for liver-targeted nanoparticle development.
Galactose-rich polysaccharide-modified lipid nanocarriers use carbohydrate-containing polymers or derivatives as surface ligands for ASGPR recognition. Compared with small GalNAc or galactose conjugates, these systems can provide multiple carbohydrate residues along a polymer chain, creating a broader surface-recognition interface. Their targeting behavior depends on the distribution of galactose residues, polymer conformation, surface density, and the accessibility of the receptor-binding groups. Arabinogalactan and pullulan are representative polysaccharides that have been investigated for carbohydrate-mediated liver targeting. Their structures can contain galactose-associated sugar units, although the number, orientation, and accessibility of these residues depend on the polymer source and molecular architecture. Lactobionic acid is another relevant carbohydrate ligand because it contains a galactose moiety, but it is a small disaccharide derivative rather than a polysaccharide. These carbohydrate materials generally require a hydrophobic modification or another lipid-association strategy before they can be incorporated into a lipid nanocarrier. Palmitoylation and lauroylation introduce hydrophobic chains that can promote association with lipid components. Alternatively, a carbohydrate can be connected to a lipid anchor through a suitable chemical spacer. This produces an amphiphilic structure with a hydrophobic region associated with the particle and a hydrophilic carbohydrate region exposed to the surrounding aqueous environment.
A relevant example was reported by Warrier and colleagues in 2022. Their study developed palmitoylated and lauroylated arabinogalactan derivatives, palmitoylated and lauroylated pullulan derivatives, and a lactobionic acid-adipic acid dihydrazide conjugate (LAD). These materials were incorporated into drug-loaded nanostructured lipid carriers (NLCs) to investigate ASGPR-oriented surface functionalization. The researchers evaluated ligand structures through molecular interaction analysis and cellular uptake studies, identifying LAD-decorated NLCs as the formulation with the highest uptake in their experimental comparison. The study provides evidence for carbohydrate-modified lipid nanocarriers, but its NLC systems should not be equated with conventional ionizable LNPs. Another related example is Gal-HA/SIL-SLNPs, reported in 2024. This formulation used galactose-functionalized hyaluronic acid to coat cationic solid lipid nanoparticles containing silybin. The design combined galactose-mediated ASGPR recognition with hyaluronic acid-associated CD44 interactions. It illustrates how carbohydrate-containing polymer layers can be used to construct dual-recognition lipid nanocarriers, although the carrier was an SLNP rather than a conventional LNP.
Several structural characteristics should be evaluated when considering these systems:
These systems may be considered when a multivalent carbohydrate surface or a polymer-associated protective layer is required. They are also relevant when a simple monosaccharide-lipid conjugate does not provide the desired surface architecture. However, the current research evidence for arabinogalactan- and pullulan-modified systems is more directly associated with NLCs than with conventional nucleic acid LNPs. Their application to ionizable LNPs should therefore be treated as a formulation-development opportunity rather than an already established general platform.
Preparation requires control of both carbohydrate modification and lipid-particle assembly. The appropriate route depends on whether the objective is to produce a polymer-lipid conjugate, adsorb a carbohydrate-containing polymer onto a particle surface, or construct a solid or nanostructured lipid carrier. These architectures should not be treated as interchangeable because their lipid organization and payload-loading mechanisms can differ.
Step 1: Selection and preparation of the carbohydrate ligand. Arabinogalactan, pullulan, or lactobionic acid can be selected according to carbohydrate composition, molecular weight, solubility, and intended surface presentation. The polymer should be characterized before modification to establish its molecular-weight distribution and available functional groups.
Step 2: Introduction of hydrophobic functionality. Polysaccharides can be modified through reactions that introduce palmitoyl, lauroyl, or other suitable hydrophobic groups. The degree of substitution should be controlled because insufficient hydrophobic modification may lead to poor lipid association, whereas excessive modification may cause aggregation or reduce carbohydrate accessibility. For lactobionic acid, a suitable spacer or linker chemistry can be used to connect the carbohydrate to the intended carrier-associated structure.
Step 3: Purification and verification of the modified polymer. Dialysis, ultrafiltration, precipitation, or chromatographic methods can be considered to remove unreacted carbohydrate, free fatty acids, coupling reagents, and low-molecular-weight byproducts. NMR and FTIR can help confirm the introduction of hydrophobic groups, while suitable chromatographic or mass-based methods can characterize the modified polymer.
Step 4: Lipid nanocarrier preparation. For NLC and SLNP architectures, emulsification, solvent diffusion, homogenization, or other suitable lipid-particle preparation methods can be evaluated. The carbohydrate-modified amphiphile can be introduced during particle formation or used for subsequent surface modification. For a conventional LNP, a compatible lipid anchor or PEG-lipid structure may be needed to incorporate the carbohydrate ligand into the lipid assembly. Solid lipid nanoparticles represent a related carrier category, but their internal lipid organization and preparation process differ from those of ionizable LNPs.
Step 5: Surface modification and formulation adjustment. If the polymer is introduced after particle formation, the incubation conditions, polymer-to-lipid ratio, temperature, and ionic strength should be controlled. If it is incorporated during assembly, the effects on particle formation, payload loading, and lipid organization should be evaluated. The carbohydrate-conjugated lipid nanoparticle development approach provides a relevant framework for investigating carbohydrate-lipid surface architectures.
The final process should be selected according to the intended carrier. A process developed for an NLC should not be transferred directly to an ionizable LNP without assessing lipid compatibility, particle formation, and payload retention. This distinction is especially important when moving from hydrophobic small-molecule loading to nucleic acid encapsulation.
Purification should remove unbound polysaccharides, unreacted hydrophobic modifiers, residual solvents, and other soluble components while retaining the surface-associated carbohydrate layer. Because polymer chains may have a broad molecular-weight distribution and can associate with lipid particles through multiple interactions, separation may be more challenging than for small-molecule ligands.
Dialysis and ultrafiltration: These methods can remove small-molecule reagents and facilitate buffer exchange. Membrane selection should account for polymer molecular weight and particle size because free high-molecular-weight polysaccharides may be retained together with the nanoparticles.
Size-exclusion chromatography: Can separate particle-associated material from smaller soluble components. Its effectiveness depends on the hydrodynamic-size difference between the nanocarriers and free polymer. Fraction analysis should be performed to confirm particle recovery and the removal of unbound carbohydrate.
Centrifugation and washing: May be considered for concentrating selected lipid nanocarrier populations. However, excessive centrifugal force or repeated washing can cause aggregation, particle loss, or dissociation of noncovalently associated polymer layers.
Characterization should establish both the physicochemical properties of the carrier and the functional availability of the carbohydrate ligand:
For NLC and SLNP systems, the physical state and organization of the lipid matrix may also influence payload retention and release. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) can be considered when thermal transitions or lipid crystallinity are relevant to the carrier design. These measurements should be selected according to the lipid matrix rather than automatically applied to every LNP formulation.
Functional characterization is equally important. A high carbohydrate content does not necessarily indicate that the receptor-recognition groups are exposed. Therefore, surface ligand quantification should be combined with ASGPR-binding analysis and cellular uptake studies. The resulting information helps determine whether poor targeting originates from insufficient ligand incorporation, inaccessible sugar residues, or incompatibility with the underlying lipid carrier.
Intravenous administration can be considered when systemic delivery to hepatocytes is the intended objective. Following administration, carbohydrate-modified particles encounter plasma proteins and hepatic tissue interfaces. Their final distribution depends on polymer size, surface density, particle charge, lipid composition, and the stability of the carbohydrate layer.
Polymer-layer density: A sufficient carbohydrate layer is needed to provide accessible ASGPR-recognition sites. However, excessive polymer coverage can increase particle size, create steric barriers, or promote interactions with other biological components. The polymer-to-lipid ratio should therefore be optimized through a controlled formulation screen.
Surface charge and hydration: Polysaccharide modification can alter surface charge and hydration behavior. These changes may influence protein adsorption, particle dispersion, and cellular association. Surface charge should be evaluated together with particle size and ligand accessibility rather than used as an independent indicator of targeting performance.
Carrier-specific delivery: NLCs and SLNPs may be suitable for certain hydrophobic payloads, while ionizable LNPs are frequently considered for nucleic acid delivery. The carbohydrate modification should not be assumed to provide the same intracellular release behavior across these different carrier architectures.
Receptor accessibility: The carbohydrate layer should remain exposed after administration. Protein adsorption or polymer rearrangement may alter the surface presentation observed during initial characterization. Therefore, receptor accessibility should also be investigated after exposure to relevant biological media.
Payload-dependent optimization: Hydrophobic small-molecule payloads require suitable lipid-matrix compatibility and release behavior. Nucleic acid payloads require effective intracellular release and, where appropriate, endosomal escape. For the latter, the ionizable lipid composition and surface polymer layer must be optimized together.
Polysaccharide-modified carriers may also be investigated through localized administration when the target tissue is accessible and local exposure is preferred. However, route selection should consider polymer diffusion, tissue interactions, particle retention, and clearance. The same formulation may exhibit different behavior after systemic and local administration, so delivery performance should be evaluated under the intended conditions.
In vivo verification should determine whether carbohydrate modification changes particle distribution, hepatocyte association, and functional payload delivery. Because polymer-coated particles may interact with multiple biological components, it is particularly important to establish whether the observed hepatic signal is related to ASGPR recognition rather than nonspecific accumulation.
Whole-body and organ distribution: A traceable lipid component or another suitable particle-associated marker can be used to monitor distribution following administration. Imaging and quantitative tissue analysis can determine the relative accumulation in the liver and other organs. When possible, the particle-associated marker and payload should be tracked separately.
Hepatocyte association: Tissue dissociation and flow cytometry can help identify the hepatic cell populations associated with the nanocarriers. Microscopy can provide complementary spatial information. The analysis should distinguish hepatocytes from macrophages and other non-parenchymal cells.
ASGPR-dependent recognition: Free-galactose competition, receptor-blocking experiments, and comparisons with unmodified carriers can help establish the contribution of ASGPR. For polysaccharide ligands, receptor recognition should not be assumed solely from the presence of galactose-containing units because their accessibility and spatial organization may differ from those of small GalNAc conjugates.
Functional payload delivery: The appropriate readout depends on the encapsulated material. Small-molecule formulations can be evaluated through tissue payload concentration and target-related biological measurements. Nucleic acid formulations require expression, gene-silencing, or other payload-specific measurements in the intended cell population.
Carrier and payload correlation: A lipid-associated signal may persist after payload release or degradation. Therefore, dual tracking or complementary payload-specific measurements can help distinguish carrier distribution from functional cargo delivery. This is particularly important for polymer-coated carriers in which the surface layer and lipid core may have different biological retention characteristics.
The evidence from carbohydrate-modified NLC and SLNP studies provides a basis for evaluating these structures, but their results should not be directly extrapolated to conventional ionizable LNPs. Each carrier architecture requires its own assessment of particle integrity, cell-specific uptake, receptor dependence, and payload activity.
BOC Sciences can support in vitro and in vivo evaluation of carbohydrate-functionalized lipid nanocarriers, including particle distribution, cellular uptake, receptor-associated recognition, and payload-specific activity. These results can guide further adjustment of polymer molecular weight, hydrophobic substitution, surface density, and lipid composition.
Table 3. Development and Evaluation Workflow for Polysaccharide-Modified Lipid Nanocarriers.
| Development Stage | Representative Methods and Readouts |
| Polysaccharide Modification and Carrier Preparation | Palmitoylation or lauroylation of selected polysaccharides; carbohydrate-lipid conjugation; emulsification, solvent diffusion, homogenization, or suitable LNP assembly. Evaluate molecular structure, substitution degree, polymer incorporation, and particle formation. |
| In Vitro Validation | DLS, PDI, zeta potential, microscopy, NMR, FTIR, carbohydrate quantification, ASGPR binding, receptor competition, cellular uptake, and payload activity. Assess polymer retention and carbohydrate accessibility. |
| Delivery Route | Systemic intravenous administration or localized delivery according to carrier type and target accessibility. Evaluate surface-layer stability, tissue exposure, and route-dependent particle distribution. |
| In Vivo Verification | Whole-body imaging, organ distribution, tissue flow cytometry, microscopy, receptor competition, and payload-specific measurements. Assess hepatocyte association, ASGPR contribution, and functional delivery. |
BOC Sciences provides carbohydrate building-block selection, polysaccharide modification, lipid conjugation, surface functionalization, and lipid nanocarrier formulation support to help evaluate ASGPR-oriented carbohydrate delivery strategies.
Insufficient ASGPR recognition can occur even when the carbohydrate ligand has been successfully incorporated into the LNP. One common cause is poor ligand accessibility. GalNAc or galactose residues may become partially buried within the PEG layer or crowded by neighboring lipid components, preventing effective interaction with the receptor. This problem can occur when the spacer is too short, the ligand orientation is unfavorable, or the surface modification density is excessive. Ligand chemistry also influences receptor recognition. Monovalent galactose generally exhibits weaker ASGPR binding than GalNAc, while multivalent GalNAc structures depend on the spatial arrangement of their carbohydrate units. A poorly designed scaffold may prevent simultaneous receptor engagement, reducing the expected benefit of multivalent presentation. For polysaccharide-modified carriers, the distribution of galactose-containing residues and polymer conformation introduce additional sources of variability. Receptor expression is another important consideration. A formulation may show limited uptake because the selected target-cell population has insufficient accessible ASGPR, rather than because the ligand chemistry itself is unsuitable. Receptor abundance and accessibility should therefore be investigated before extensive formulation optimization.
Optimization directions: Compare different GalNAc valencies, scaffold structures, PEG spacer lengths, and Gal-lipid configurations. Evaluate ligand density over a controlled range rather than assuming that higher carbohydrate content produces stronger targeting. Measure ASGPR binding and use free-GalNAc or free-galactose competition to assess receptor-dependent recognition. For polysaccharide systems, compare molecular weight and hydrophobic substitution degree to identify a balance between surface coverage and carbohydrate accessibility. PEG shielding should be optimized together with ligand presentation rather than independently.
Unstable ligand anchoring can reduce the amount of functional carbohydrate remaining on the LNP surface during storage, dilution, or exposure to biological fluids. In lipid-integrated systems, the hydrophobic anchor may gradually dissociate from the particle membrane if its structure is poorly matched to the lipid composition. In post-insertion processes, incomplete membrane insertion can also result in a heterogeneous distribution of targeting conjugates. Direct covalent conjugation and noncovalent surface adsorption introduce different challenges. Covalent conjugation may produce incomplete coupling when reactive groups are insufficiently accessible or reaction conditions are unsuitable. Electrostatic or adsorption-based polymer modification may be weakened by changes in ionic strength, pH, and interactions with biological components. In all these cases, the amount of ligand initially added to the formulation may differ substantially from the amount ultimately retained on the particle. Another common issue is the presence of free conjugate after particle preparation. Unincorporated GalNAc-lipid or polysaccharide-lipid material may remain in the formulation and contribute to apparent carbohydrate content or receptor binding. Without effective purification and fraction analysis, ligand incorporation can be overestimated.
Optimization directions: Compare lipid-anchor structures with different hydrophobic chain lengths and membrane-association characteristics. Evaluate pre-incorporation and post-insertion under controlled conditions, and directly quantify particle-associated ligand after purification. For covalent systems, optimize activation chemistry, reactive-group availability, reaction time, and conjugation ratio. For polymer-associated systems, evaluate coating stability under relevant buffer and biological-media conditions. Purification should be designed to distinguish free conjugates from particle-associated material while maintaining high particle recovery.
Surface modification can disturb the physicochemical balance of an established LNP formulation. Excessive GalNAc-lipid incorporation, high polysaccharide substitution, or unfavorable polymer-to-lipid ratios may alter particle packing and increase interparticle interactions. In some formulations, the introduction of a carbohydrate layer may increase hydrodynamic diameter or promote particle bridging, resulting in a higher PDI and reduced colloidal stability. Electrostatic interactions can create additional formulation challenges. For example, positively charged lipid particles may undergo charge neutralization or aggregation when exposed to negatively charged polymer components. Changes in buffer composition, ionic strength, and pH can further influence particle association. In hydrophobic payload formulations, surface modification may also change the organization of the lipid matrix and affect drug retention. Payload loss is particularly important for nucleic acid LNPs. Prolonged incubation, unfavorable pH, excessive mixing, or unsuitable purification conditions may reduce encapsulation efficiency or compromise RNA integrity. A particle can retain an apparently acceptable size distribution while experiencing a reduction in payload retention or functional delivery.
Optimization directions: Establish the physicochemical properties of the unmodified LNP before introducing the targeting ligand. Screen ligand-to-lipid ratios, lipid composition, buffer conditions, and mixing parameters systematically. Reduce the surface modifier fraction when excessive particle growth or aggregation occurs. Evaluate the effects of incubation time and temperature during post-insertion, and avoid unnecessary exposure of encapsulated payloads to reactive or unfavorable conditions. For polymer-modified carriers, adjust hydrophobic substitution and polymer molecular weight to limit particle bridging. LNP encapsulation efficiency optimization can help identify formulation variables associated with payload loss.
One of the most important challenges in ASGPR-targeted LNP development is the difference between liver accumulation and productive hepatocyte delivery. A particle may accumulate in the liver because of its size, surface charge, protein adsorption, or uptake by hepatic macrophages without achieving substantial ASGPR-mediated internalization. Consequently, increased liver-associated fluorescence does not necessarily indicate improved delivery to the intended cell population. Another limitation occurs after cellular uptake. ASGPR-associated endocytosis may increase particle internalization, but the encapsulated payload can remain trapped in endosomal compartments or undergo intracellular degradation. This is particularly relevant for nucleic acid delivery, where functional activity generally requires the payload to reach the appropriate intracellular location. The targeting ligand may also change during circulation. Protein adsorption can mask carbohydrate residues, while weakly associated lipid conjugates may dissociate from the particle. These changes can reduce receptor accessibility even when the initial formulation shows favorable binding properties.
Optimization directions: Separate organ-level distribution, hepatocyte-specific uptake, intracellular localization, and payload activity into distinct evaluation endpoints. Compare modified and unmodified LNPs using suitable target-cell and receptor-blocking controls. Analyze particle-associated signals in hepatocytes and non-parenchymal cell populations to identify the major sites of accumulation. If endosomal retention is observed, evaluate ionizable lipid composition, membrane-disruptive properties, and intracellular release behavior. For nucleic acid formulations, reporter expression or gene-silencing measurements should be included to establish productive delivery. LNP transfection troubleshooting services can support the investigation of poor cellular delivery and payload activity.
BOC Sciences has experienced technical specialists who can help investigate ligand accessibility, conjugation efficiency, surface heterogeneity, particle aggregation, payload loss, receptor recognition, and insufficient hepatocyte delivery through systematic formulation analysis and optimization.
The selection of carbohydrate ligands and lipid building blocks determines the chemical structure, surface presentation, and receptor-recognition characteristics of ASGPR-targeted nanocarriers. BOC Sciences can support the selection of GalNAc and galactose derivatives, multivalent carbohydrate scaffolds, hydrophilic spacers, lipid anchors, and galactose-containing polysaccharide materials according to the intended carrier architecture. For GalNAc-based systems, material selection can focus on ligand valency, scaffold geometry, spacer length, and lipid-anchor structure. For galactose-functionalized systems, the availability of suitable reactive groups and the accessibility of the carbohydrate headgroup are important considerations. For polysaccharide-modified carriers, molecular weight, hydrophobic substitution degree, and polymer solubility should be evaluated before conjugation. Custom synthesis can be considered when standard building blocks do not provide the required structure or functional groups. The objective is to obtain materials with suitable chemical identity, purity, and compatibility with the intended LNP preparation process.
BOC Sciences supports the development of carbohydrate-lipid conjugates and their incorporation into lipid nanocarriers. Potential strategies include multivalent GalNAc scaffold synthesis, Gal-PEG-lipid preparation, polysaccharide hydrophobic modification, pre-incorporation during LNP formation, and post-assembly surface functionalization. Development can focus on the relationship between conjugate structure and particle-surface properties. For GalNAc systems, important parameters include scaffold geometry, PEG spacer length, lipid-anchor retention, and ligand density. For Gal systems, the presentation of terminal galactose residues and the balance between surface shielding and receptor accessibility should be evaluated. For polysaccharide-based carriers, the degree of hydrophobic modification and polymer distribution can be adjusted to improve particle association and surface uniformity. The appropriate conjugation strategy depends on the original lipid composition, payload sensitivity, and desired surface architecture. BOC Sciences can support nanoparticle functionalization and formulation-specific surface modification to investigate these requirements.
The performance of ASGPR-targeted LNPs depends on the compatibility between the carbohydrate layer and the underlying lipid nanoparticle core. BOC Sciences can support lipid-component selection, formulation screening, payload encapsulation, particle preparation, and process optimization according to the intended delivery application. For nucleic acid formulations, development can focus on ionizable lipid selection, helper phospholipid content, cholesterol composition, PEG-lipid fraction, and payload-to-lipid ratio. For small-molecule payloads, the formulation can be adjusted according to drug solubility, lipid compatibility, loading capacity, and release characteristics. Lipid nanoparticle encapsulation and nucleic acid encapsulation in LNPs provide relevant support for different payload requirements. Purification strategies can be evaluated to remove unbound carbohydrate conjugates, free payload, residual solvents, and reaction byproducts while maintaining particle recovery. Physicochemical characterization can include particle size, PDI, zeta potential, morphology, lipid composition, ligand incorporation, encapsulation efficiency, and colloidal stability. These measurements provide a basis for comparing different ASGPR-targeting architectures and identifying formulation-related causes of poor performance. BOC Sciences can also support LNP process optimization to investigate the combined effects of lipid ratios, mixing conditions, surface modification, and purification parameters.
Biological evaluation is essential for determining whether carbohydrate functionalization produces the intended receptor-associated delivery effect. BOC Sciences can support cellular binding and uptake analysis, receptor-competition experiments, intracellular localization, and payload-specific functional measurements using suitable target and control cell models. For ASGPR-targeted systems, evaluation can include comparison of modified and unmodified LNPs, free-carbohydrate competition, receptor-expression analysis, and cellular uptake measurements. These experiments can help distinguish ASGPR-associated recognition from nonspecific nanoparticle interactions. Nanoparticle intracellular localization detection can provide additional information about intracellular trafficking and payload-release limitations. In vivo evaluation can be designed to investigate whole-body distribution, organ accumulation, hepatocyte association, and functional payload delivery. Imaging-based tracking can be combined with tissue-level quantitative analysis and cell-specific measurements to distinguish particle accumulation from productive delivery. For nucleic acid formulations, LNP endosomal escape evaluation can provide complementary information about intracellular delivery limitations. By integrating physicochemical characterization with cellular and in vivo evaluation, BOC Sciences can help researchers identify the structural and formulation parameters that influence ASGPR-targeted LNP performance and guide subsequent development.
Table 4. BOC Sciences Services for ASGPR-Targeted LNP Development.
| Service Name | Description | Inquiry |
| ASGPR Ligand and Lipid Building-Block Selection | Selection of GalNAc, galactose, carbohydrate scaffolds, PEG spacers, and lipid anchors according to ligand structure and intended nanocarrier architecture. | Inquiry |
| Custom GalNAc and Gal-Lipid Conjugate Synthesis | Custom synthesis of multivalent GalNAc-lipid conjugates, Gal-PEG-lipids, and other carbohydrate-associated lipid building blocks with selected spacer and anchor structures. | Inquiry |
| ASGPR-Targeted LNP Surface Functionalization | Development of carbohydrate conjugation, lipid incorporation, and post-assembly surface modification strategies with optimization of ligand accessibility and surface density. | Inquiry |
| Custom LNP Formulation and Payload Encapsulation | Selection of ionizable lipids, helper phospholipids, cholesterol, and PEG-lipids, followed by formulation screening and payload encapsulation optimization. | Inquiry |
| ASGPR-Targeted LNP Purification and Characterization | Evaluation of particle size, PDI, zeta potential, morphology, ligand incorporation, payload encapsulation, and colloidal stability after surface modification. | Inquiry |
| ASGPR-Dependent Cellular Uptake Evaluation | Cellular binding and uptake analysis, receptor-competition experiments, target-cell comparison, intracellular localization, and functional payload delivery assessment. | Inquiry |
| In Vivo Biodistribution and Functional Delivery Evaluation | Whole-body imaging, organ distribution, hepatocyte-associated uptake, tissue-level analysis, and payload-specific expression, silencing, or editing measurements. | Inquiry |
ASGPR-targeted lipid nanoparticles provide a versatile approach for improving hepatocyte recognition and delivering research payloads to the liver. Multivalent GalNAc-lipid-integrated LNPs offer strong receptor-recognition potential through organized carbohydrate presentation, while galactose-lipid-conjugated LNPs provide an alternative surface-functionalization strategy based on terminal galactose recognition. Galactose-rich polysaccharide-modified lipid nanocarriers extend these approaches through polymer-associated carbohydrate presentation, although much of the available evidence for these structures comes from NLC and SLNP systems rather than conventional ionizable LNPs. Successful development requires coordinated optimization of ligand structure, valency, spacer length, lipid-anchor retention, surface density, and core formulation. Purification and physicochemical characterization should be combined with receptor-dependent cellular uptake, cell-specific biodistribution, and functional payload evaluation. Importantly, hepatic accumulation should not be treated as equivalent to productive hepatocyte delivery. BOC Sciences provides carbohydrate building blocks, custom conjugate synthesis, LNP formulation, surface functionalization, purification, characterization, and cellular and in vivo evaluation support to help researchers develop ASGPR-targeted lipid nanocarriers for different payloads and delivery objectives.